Print |
Bookmark |
Font Size:
+ |
–
LCD & Medical Policy Stakeholder Meetings
Compliance Officer Meetings
Closed to members & invited guests.
State |
Date & Time |
Location |
J15 KY/OH |
February 25, 2025
2:30 – 3:30 pm ET (1:30 – 2:30 pm CT) |
Microsoft Teams |
CAC Meetings
Contractor Advisory Committee (CAC) meetings are for the purpose of discussing literature related to proposed Local Coverage Determinations (LCDs) before they're developed.
CAC members serve in an advisory capacity. All meetings are open to the public to attend and observe.
Currently, there are no scheduled meetings.
See Prior CAC Meetings below.
Open Meetings
Open Meetings are for the purpose of discussing new proposed (draft) LCDs or the revised portion of a proposed LCD in the 45-day open comment period. These meetings are not a forum to discuss specific claims, the submission of new drugs or indications, or to market forthcoming drugs or medical devices.
Open to the public.
State |
Date & Time |
Location |
Agenda |
J15 KY & OH |
June 10, 2025
4 – 5 pm ET (3 – 4 pm CT) |
Microsoft Teams |
Announcement
Registration
Topics:
Proposed/Draft LCDs not released to final:
|
J15 KY/OH |
February 25, 2025
4 – 5 pm ET (3 – 4 pm CT) |
Microsoft Teams |
Topics:
- DL40056/DA59981 – Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)
- Proposed/Draft LCDs not released to final:
|
See Prior Open Meetings below.
Provider Touch Point Meetings
Closed to members & invited guests.
State |
Date & Time |
Location |
J15 KY & OH |
June 10, 2025
6 – 7 pm ET (5 – 6 pm CT) |
Microsoft Teams |
Prior CAC Meetings
Date |
Topic |
Details |
Documentation |
02.03.2025 |
Peripheral Nerve Blocks and Ablations |
|
|
10.17.2024 |
Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) |
|
|
07.15.2024 |
MolDX: Biomarker Risk Stratification Testing in DCIS |
|
|
10.19.2023 |
Botulinum Toxins |
|
|
08.16.2023 |
Cervical Fusion |
|
|
05.25.2023 |
Non-Invasive Technology for Coronary Artery Plaque Analysis |
|
|
04.27.2023 |
Trigger Point Injections |
- Multi-Jurisdictional Host: WPS Government Health Administrators (GHA)
|
|
02.28.2023 |
RPM and RTM for Non-Implantable Devices |
- Multi-Jurisdictional Host: Novitas and First Coast Service Options
|
|
01.05.2023 |
Micro-Invasive Glaucoma Surgery (MIGS) |
|
|
11.09.2022 |
PET Scans for Inflammation and Infection |
|
|
03.10.2022 |
Sacroiliac Joint Injections and Procedures |
|
|
12.07.2021 |
MolDX: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis |
|
|
10.12.2021 |
MolDX: Molecular Testing for Risk Stratification of Upper Gastrointestinal Cancer |
|
|
09.29.2021 |
Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD) |
|
|
05.12.2021 |
Amniotic Product Injections for Musculoskeletal Indications, Non-Wound |
|
|
03.10.2021 |
Platelet Rich Plasma for Non-Wound Care |
|
|
02.11.2021 |
Epidural Interventions for Chronic Pain Management |
|
|
01.11.2021 |
Molecular Diagnostic Testing for Pathogens |
|
|
11.18.2020 |
Electroretinography |
|
|
05.28.2020 |
Facet Joint and Medical Nerve Branch Procedures |
|
|
06.29.2019 |
Pharmacogenomics |
|
|
03.20.2019 |
Vertebral Augmentation |
|
|
Prior Open Meetings
State |
Date |
Topics |
Documentation |
J15 KY & OH |
02.25.2025 |
- DL40056/DA59981 – Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)
|
|
J15 OH |
10.30.2024 |
- MolDX: Genetic Testing for Heritable Thoracic Aortic Disease (DL39938/DA59860)
- MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (DL4000/DA59919)
- MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (DL39940/DA59862)
- Intravertebral Disc Injections (Via Disc) 0627T (DL39958/DA59880)
- Non-invasive Vascular (open to revised section only) (DL34045/DA56697)
|
|
J15 KY |
10.29.2024 |
- MolDX: Genetic Testing for Heritable Thoracic Aortic Disease (DL39938/DA59860)
- MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (DL4000/DA59919)
- MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (DL39940/DA59862)
- Intravertebral Disc Injections (Via Disc) 0627T (DL39958/DA59880)
- Non-invasive Vascular (open to revised section only) (DL34045/DA56697)
|
|
J15 KY/OH |
06.18.2024 |
- DL37578/DA56491 – MIGS
- DL39857/DA59726 – Botulinum Toxins
- DL39840/DA59716 – Quantitative Coronary Plaque Analysis derived from Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QTC)/Coronary Plaque Analysis (AI-CPA)
|
|
J15 KY/OH |
05.16.2024 |
- DL39756/DA59618 – Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
- DL39802/DA59682 – Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ)
|
|
J15 KY/OH |
02.13.2024 |
- DL38773 – Facet Joint Interventions for Pain Management
- DA58346 – Billing and Coding: Facet Joint Interventions for Pain Management
- DL39741 – Cervical Fusion
- DA 59608 – Billing and Coding: Cervical Fusion
|
|
J15 OH |
11.08.2023 |
- MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
- MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
- MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
- MolDX: Molecular Testing for Solid Organ Allograft Rejection
- Implantable Continuous Glucose Monitors (I-CGM)
- Trigger Point Injections (TPI)
|
|
J15 KY |
11.07.2023 |
- MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
- MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
- MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
- MolDX: Molecular Testing for Solid Organ Allograft Rejection
- Implantable Continuous Glucose Monitors (I-CGM)
- Trigger Point Injections (TPI)
|
|
J15 KY/OH |
07.11.2023 |
- Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
- Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)
- Micro-Invasive Glaucoma Surgery (MIGS)MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
|
|
J15 KY/OH |
06.22.2023 |
- Urinary Biomarkers for Chronic Pain Management
|
|
J15 KY/OH |
05.17.2023 |
|
|
J15 KY/OH |
02.21.2023 |
- Cosmetic and Reconstructive Surgery
- Positron Emission Tomography (PET) for Inflammation and Infection Special Histochemical Stains and Immunohistochemical Stains
- Transthoracic Echocardiography (TTE)
|
|
J15 OH |
10.26.2022 |
- Allogenic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
- MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
- MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
- Sacroiliac Joint Injections and Procedures
- Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
- Transtelephonic Spirometry
- Urine Drug Testing
|
|
J15 KY |
10.25.2022 |
- Allogenic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
- MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
- MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
- Sacroiliac Joint Injections and Procedures
- Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
- Transtelephonic Spirometry
- Urine Drug Testing
|
|
J15 KY/OH |
06.21.2022 |
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia and Neoplasia
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer
- Prostate Cancer Detection with IsoPSA™
- Transcranial Magnetic Stimulation (TMS)
|
|
J15 KY/OH |
02.22.2022 |
- Non-Invasive Fractional Flow Reserve (FFR) for Stable Ischemic Heart Disease
|
|
J15 KY/OH |
10.13.2021 |
- Colon Capsule Endoscopy (CCE)
- Prostate Cancer Detection with IsoPSA™
|
|
J15 KY/OH |
07.13.2021 |
- Epidural Procedures for Pain Management
- MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
- MolDX: Melanoma Risk Stratification Molecular Testing
- MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
- MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
|
|
J15 KY/OH |
02.23.2021 |
- Off-Label Use of Rituximab and Rituximab Biosimilars
- Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF)
|
|
J15 KY/OH |
10.13.2020 |
- Non-Invasive Flow Reserve (FFR) for Stable Ischemic Heart Disease
|
|
J15 KY/OH |
10.13.2020 |
- Colon Capsule Endoscopy (CCE)
- Controlled Substance Monitoring and Drugs of Abuse Testing
- Magnetic Resonance Guided Focused Ultrasound Surgery System (MRgFUS) for the Treatment of Neurologic Conditions
- MolDX: Minimal Residual Disease Testing (MRDT) for Cancer
|
|
J15 KY/OH |
10.13.2020 |
- Facet Joint Interventions for Pain Management
|
|
J15 KY/OH |
02.18.2020 |
- Vitamin D Assay Testing (L33996) Reconsideration
|
|
J15 OH |
10.30.2019 |
- Open Draft/Revised LCD Discussion
|
|
J15 KY |
10.29.2019 |
- Open Draft/Revised LCD Discussion
|
|
J15 KY/OH |
06.18.2019 |
- Open Draft/Revised LCD Discussion
|
|
J15 KY/OH |
05.07.2019 |
- Drug Interaction Testing and Multiple MolDX Draft Policies
|
|
J15 KY/OH |
02.12.2019 |
- MolDX: DecisionDx – Melanoma
|
|
Updated: 05.19.2025